INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 146 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $10,562,355 | +13.2% | 955,005 | +37.5% | 0.01% | +8.3% |
| Q1 2023 | $9,328,975 | +305667.8% | 694,637 | +181.6% | 0.01% | +200.0% |
| Q4 2022 | $3,051 | -99.9% | 246,635 | +34.7% | 0.00% | 0.0% |
| Q3 2022 | $2,554,000 | +17.6% | 183,106 | +16.4% | 0.00% | +33.3% |
| Q2 2022 | $2,172,000 | -6.3% | 157,293 | +10.4% | 0.00% | 0.0% |
| Q1 2022 | $2,319,000 | -0.1% | 142,525 | 0.0% | 0.00% | +50.0% |
| Q4 2021 | $2,322,000 | +47.1% | 142,525 | +34.0% | 0.00% | 0.0% |
| Q3 2021 | $1,579,000 | – | 106,323 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |